Shell Asset Management Co. Purchases 34,178 Shares of Pfizer Inc. $PFE

Shell Asset Management Co. lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 61.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 89,658 shares of the biopharmaceutical company's stock after acquiring an additional 34,178 shares during the period. Shell Asset Management Co.'s holdings in Pfizer were worth $2,173,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Pacer Advisors Inc. increased its position in Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the period. Amundi increased its position in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Nuveen LLC acquired a new position in Pfizer in the 1st quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. increased its position in Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the period. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.41.

Pfizer Stock Down 2.3%

Shares of NYSE PFE opened at $25.67 on Thursday. The firm has a market cap of $145.95 billion, a PE ratio of 13.65, a P/E/G ratio of 0.86 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company's fifty day simple moving average is $24.79 and its 200 day simple moving average is $24.15. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.